About Ultivue
Ultivue is a Healthcare company based in Cambridge (United States) founded in 2015. It operates as a provider of test panels for personalized cancer therapies. Ultivue has raised $105.23 million across 5 funding rounds from investors including Applied Materials, Arch Venture Partners and Ally Bridge Group. Ultivue offers products and services including OmniVUE, U-VUE, InSituPlex, and STARVUE. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is Ultivue, Inc. Its competitors include Personalis, OncoDNA, Strata Oncology, RootPath Genomics and Precede and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Ultivue was founded in 2015 and is based in Cambridge, United States, within the biotechnology sector focused on oncology. Biomarker panels are created to assess the immune landscape, supporting precision therapies. Key products include FixVUE, FlexVUE, and U-VUE. Multiplex immunofluorescence services are delivered using proprietary InSituPlex technology, which involves DNA-barcoding and antibody staining for tissue analysis.
- Headquarters Cambridge, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ultivue.com
- Social LinkedIn X Facebook YouTube
- Legal Name Ultivue, Inc.
- Total Equity Funding$105.23M (USD)
in 5 rounds
- Latest Funding Round$3.32M (USD), Series D
Jul 2024
- InvestorsApplied Materials
& 8 more
Products & Services of Ultivue
Ultivue offers a comprehensive portfolio of products and services, including OmniVUE, U-VUE, InSituPlex, and STARVUE.
Offers core biomarkers for cancer research analysis
Provides customized biomarker solutions for research needs
Enables ultrasensitive detection of biomarkers in tissues
Delivers AI-enhanced spatial phenomics for tumor microenvironments
Funding Insights of Ultivue
Ultivue has successfully raised a total of $105.23M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $3.32 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $105.23M
- Total Rounds 5
- Last Round Series D — $3.32M
- First Round $5.15M
(Jun 2015)
- Investors Count 9
All 5 funding rounds of Ultivue with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $3.32M | Series D | – | – | – |
| Apr 2021 | $50M | Series D | – | – | |
| Jun 2019 | $26.5M | Series C | – | Northpond Ventures | |
| Jan 2018 | $20.25M | Series B | – | Arch Venture Partners | |
| Jun 2015 | $5.15M | Series A | – | – | – |
9 investors in total: 9 institutional.
Investors in Ultivue
Ultivue has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Applied Materials, Arch Venture Partners and Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China | |
Investment management services are provided focusing on healthcare innovation. | – | puravidainvestments.com | New York, United States | |
Venture capital firm focused on multiple sectors | – | taocap.com | Marlborough, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | – | 6dimensionscapital.com | Pudong, China | |
- | – | yonghuacapital.com.cn | - | |
A venture capital firm focused on life sciences investments. | – | sangelvc.com | Shenzhen, China | |
Materials engineering solutions are supplied for semiconductor and electronics industries. | 1967 | appliedmaterials.com | Santa Clara, United States |
Investor details for Ultivue
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ultivue
24 people are tracked at Ultivue (7 in leadership, 5 in board & advisors, 12 in team).
| Name | Role | Group |
|---|---|---|
David Walt | Co-Founder and Director | Leadership |
Je H. Lee | Head, Science & Technology | Leadership |
A. Fawad Faruqi | Vice President Business Development | Leadership |
Angela Vasaturo | Director Scientific Affairs | Leadership |
Jay Lee | Head of Science and Technology | Leadership |
Edyta Olejnik | Director Of Manufacturing | Leadership |
Rubén Cárdenes | Director AI Engineering | Leadership |
Keith Crandell | Director | Board & advisors |
Peng Yin | Director | Board & advisors |
Fenel Eloi | Director | Board & advisors |
Andrea Jackson | Director | Board & advisors |
Ralf Jungmann | Co-Founder | Board & advisors |
Matt Andjus | Senior Recruiter | Team |
Deena Nieuwenhuis | Accounting Manager | Team |
Noelle Durling, CPA | Corporate Controller | Team |
Ronald McDermott | Senior Manager, Technical Accounting & Financial Reporting | Team |
Vanessa Miller | Accountant | Team |
Jonathan Samson | Regional Sales Manager US East and Canada | Team |
Will Gooch | Senior Quality Control Analyst | Team |
Hanaa Dembri | Junior Project Coordinator | Team |
4 more people are available in the full profile.
Complete people profiles for Ultivue
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ultivue
3 dated milestones of Ultivue across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Ultivue is founded.
- Funding First funding round of $5.2M.
- Funding Latest funding round, Series D, of $3.3M.
Competitors of Ultivue
Ultivue has 9 listed competitors in our database, 9 of them funded. They include Personalis, OncoDNA, Strata Oncology, RootPath Genomics and Precede, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| strataoncology.com | 2015 | Ann Arbor, United States | $139.15M | 125 | Genetic sequencing is provided for late-stage cancer patients. | |
| rootpath.com | 2017 | Cambridge, United States | $68M | 16 | Immunotherapy platform is developed for personalized cancer treatment. | |
| precede.bio | 2021 | Boston, United States | $57M | – | Circulating chromatin is profiled via liquid-biopsy platform for cancer diagnosis. | |
| functiononcology.com | 2018 | San Diego, United States | $28M | 16 | Cancer therapeutics are developed using a CRISPR-enabled platform. | |
| actgenomics.com | 2014 | Taipei, Taiwan | $20.5M | – | Genomics services for cancer clinical and research needs are delivered. | |
| onecelldx.com | 2021 | Cupertino, United States | $16M | – | Offers genomic testing and AI tools for cancer diagnosis and monitoring. | |
| 4basecare.com | 2018 | Bengaluru, India | $9.06M | – | Developer of precision oncology solutions using advanced genomics and digital health technology |
Detailed competitors of Ultivue
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ultivue
The website of Ultivue (ultivue.com) receives about 3K visits a month.
- Monthly visits3K
▲ 67.1% vs previous month
Top companies in Oncology
10 companies that operate in the same segment as Ultivue (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ultivue
Complete news archive for Ultivue
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ultivue
Ultivue was founded in 2015.
Ultivue is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ultivue is a funded company, having raised a total of $105.23M across 5 funding rounds to date. The company's 1st funding round was a Series A of $5.15M, raised on Jun 2015.
Ultivue was founded in 2015 and is based in Cambridge, United States, within the biotechnology sector focused on oncology. Biomarker panels are created to assess the immune landscape, supporting precision therapies. Key products include FixVUE, FlexVUE, and U-VUE. Multiplex immunofluorescence services are delivered using proprietary InSituPlex technology, which involves DNA-barcoding and antibody staining for tissue analysis.
Ultivue's top competitors include Personalis, OncoDNA and ACT Genomics.
Ultivue offers OmniVUE, U-VUE, InSituPlex, and STARVUE.
Ultivue has 9 investors. Key investors include Applied Materials, Arch Venture Partners, Ally Bridge Group, Pura Vida, and Tao Capital Partners.
Ultivue operates through Ultivue, Inc..